期刊文献+

冠心病伴心房颤动患者B型脑钠肽、血管紧张素Ⅱ及左心房内径的检测及临床意义 被引量:1

下载PDF
导出
摘要 目的探讨冠心病伴发不同类型的心房颤动(房颤)患者中B型脑钠肽(BNP)、血管紧张素Ⅱ(AngⅡ)的水平左心房内径(LAD)的检测及临床意义。方法临床上已确诊为冠心病的患者共178例,分为单纯冠心病无房颤组63例,冠心病合并阵发性房颤组55例,冠心病合并持续性房颤患者60例,检测左心室射血分数(LVEF)、LAD、BNP及AngⅡ水平。结果冠心病合并持续性房颤组及冠心病合并阵发性房颤组,其BNP、AngⅡ及LAD均高于单纯冠心病组(P<0.05);而冠心病合并持续性房颤组其BNP、AngⅡ及LAD均高于冠心病合并阵发性房颤组(P<0.05),而三组之间LVEF比较,差异无统计学意义(P>0.05)。冠心病合并持续性房颤组和冠心病合并阵发性房颤组血BNP水平与AngⅡ明显相关,血BNP水平与LAD明显相关(P<0.05)。结论测定血浆中的BNP、AngⅡ及LAD可有效预测房颤的发生、发展,评估治疗效果。
作者 吴帆
出处 《中国实用医药》 2013年第30期68-69,共2页 China Practical Medicine
  • 相关文献

参考文献2

二级参考文献13

  • 1Lee YA, Liang CS, Lee MA, et al. Local stress, not systemic factors, regulate gene expression of the cardiac renninangiotensin system in vivo: a comprehensive study of all components in the dog. Proc Natl Acad Sci USA, 1996, 93:11035-11040.
  • 2Ikram H. The rennin-angiotensin-aldosterone system and cardiac ischemia. Heart, 1996, 76 (supply3) :560-567.
  • 3Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin Ⅱ type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol, 2003, 41:2197-2204.
  • 4Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction.Circulation, 1999, 100:376-380.
  • 5Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation, 2002, 106:331-336.
  • 6Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol,2000,35:1669-1677.
  • 7Everett TH, Li H, Mangrum JM, et al. Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation, 2000,102:1454-1460.
  • 8Pfeffer MA. Enhancing cardiac protection after myocardial infarction rationale for newer clinical trials of angiotensin Ⅱ receptor blockers. Am Heart J,2000,139: s23-s28.
  • 9Goette A, Arndt M, Rocken C, et al. Regulation of angiotensin Ⅱ receptor subtypes during atrial fibrillation in humans. Circulation, 2000, 101:2678-2681.
  • 10Li D, Shinagawa K, Pang L, et al. Effects of angiotensinconverting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation, 2001,104:2608-2614.

共引文献374

同被引文献9

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部